Forest Labs, Glenmark End Blood Pressure Drug IP Fight
Pharmaceutical company Forest Laboratories Inc. said Wednesday it had agreed to drop patent infringement claims in a multidistrict litigation against generic-drug maker Glenmark Pharmaceuticals Ltd. over beta-blocker Bystolic after the two...To view the full article, register now.
Already a subscriber? Click here to view full article